Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Sold by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. cut its holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 6.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 347,610 shares of the company’s stock after selling 22,378 shares during the period. Charles Schwab Investment Management Inc. owned 0.28% of Atossa Therapeutics worth $528,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in ATOS. Intech Investment Management LLC purchased a new stake in shares of Atossa Therapeutics in the third quarter valued at $29,000. XTX Topco Ltd purchased a new position in Atossa Therapeutics during the second quarter worth approximately $29,000. SG Americas Securities LLC boosted its holdings in shares of Atossa Therapeutics by 254.3% in the 3rd quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock valued at $64,000 after purchasing an additional 30,037 shares during the last quarter. Rhumbline Advisers purchased a new stake in shares of Atossa Therapeutics during the 2nd quarter valued at $161,000. Finally, Bank of New York Mellon Corp increased its holdings in shares of Atossa Therapeutics by 3,160.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 411,667 shares of the company’s stock worth $490,000 after buying an additional 399,041 shares during the last quarter. Hedge funds and other institutional investors own 12.74% of the company’s stock.

Atossa Therapeutics Stock Performance

Atossa Therapeutics stock opened at $0.99 on Thursday. The firm has a market capitalization of $124.54 million, a PE ratio of -4.50 and a beta of 1.21. Atossa Therapeutics, Inc. has a one year low of $0.70 and a one year high of $2.31. The stock’s 50 day moving average price is $1.33 and its 200 day moving average price is $1.32.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ATOS shares. Ascendiant Capital Markets lifted their price objective on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a research note on Monday, December 9th. StockNews.com downgraded shares of Atossa Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, November 18th. Finally, HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Atossa Therapeutics in a report on Thursday, December 12th.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.